GLP-1 medications

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic the GLP-1 hormone your gut releases after eating. They lower blood sugar, slow gastric emptying, и reduce appetite. Originally developed for type 2 diabetes, several are now FDA-approved for chronic weight management.

FDA-approved GLP-1 (and GLP-1/GIP) medications include: Ozempic, Rybelsus и Wegovy (semaglutide); Mounjaro и Zepbound (tirzepatide); Saxenda и Victoza (liraglutide); Trulicity (dulaglutide); Byetta и Bydureon (exenatide). Compounded semaglutide и tirzepatide are also widely used via telehealth.

GLP-1 drugs activate GLP-1 receptors to: (1) stimulate insulin release when blood sugar is high, (2) suppress glucagon (which raises blood sugar), (3) slow gastric emptying so you feel full longer, и (4) act on brain appetite centers to reduce hunger и "food noise". Tirzepatide also activates GIP receptors for added effect.

The most common side effects are gastrointestinal: nausea (most frequent, ~20-44% of patients), vomiting, diarrhea, constipation, и abdominal pain. These are usually mild-to-moderate и improve as the body adjusts, especially with slow dose titration. Rare but serious risks include pancreatitis и gallbladder issues.

In head-to-head data, tirzepatide (Zepbound) produced the greatest average weight loss (~22% at 72 weeks in SURMOUNT-1) vs semaglutide (Wegovy ~15% at 68 weeks in STEP-1). Tirzepatide is a dual GLP-1/GIP agonist, which may explain its edge.

The main downsides are: frequent GI side effects (nausea, vomiting, diarrhea, constipation), especially during dose increases; high cost without insurance ($1,000+/month for brand); the need for ongoing use — weight tends to return after stopping; muscle-mass loss alongside fat loss if protein и resistance training are neglected; and rare but serious risks like pancreatitis, gallbladder disease, и a boxed thyroid-tumor warning.

For most people, yes. The common gastrointestinal side effects (nausea, diarrhea, constipation) are usually worst during the first weeks и after each dose increase, then ease as the body adapts — often within a few weeks to a couple of months. Slow dose titration, smaller meals, и staying hydrated reduce them. Side effects that are severe, persistent, or include intense abdominal pain warrant contacting your prescriber.

GLP-1 drugs are generally avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, type 1 diabetes, or known hypersensitivity. They are not recommended during pregnancy or breastfeeding и are used cautiously in those with severe gastrointestinal disease (e.g. gastroparesis). Always review your full medical history with a licensed prescriber.

Semaglutide has multi-year safety data showing the benefits are broadly maintained, but long-term considerations include: gallbladder problems (gallstones), possible loss of lean muscle mass with large weight loss, и the boxed thyroid-tumor warning derived from rodent studies (no confirmed human causation). Weight regain is common after stopping. Newer molecules have shorter track records, so long-term data continues to accumulate.

GLP-1 receptor agonists act on the pancreas (insulin и glucagon regulation), stomach и gut (slowed emptying, the source of most GI side effects), the brain (appetite и "food noise" centers in the hypothalamus), и indirectly the liver и heart — several have shown cardiovascular benefit. The gallbladder и thyroid are the organs tied to their notable safety warnings.